Delivery Order SPE2DB25D7057-SPE2DB25FXVQU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,629.42 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count packages). This firm fixed-price, non-set-aside delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Febuxostat 80 mg tablets (30-count supply) valued at $1,799.27. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this pharmaceutical delivery through its Corporate Office division. This award represents a single delivery order under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,001.53 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets in quantities of 30 units. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 25, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the...
- The Defense Logistics Agency awarded a delivery order valued at $2,768.65 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count units) on September 4, 2025, with completion scheduled for September 5, 2025. This delivery order represents a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Febuxostat 80 mg tablets in quantities of 30, with a contract ceiling value of $1,191.79. This is a firm fixed price delivery order with an ultimate completion date of August 21, 2025, and represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,258.08 on May 12, 2025, for the supply of Febuxostat 40 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion deadline of May 13, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Febuxostat 40 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with a ceiling value of $1,394.19, with an ultimate completion date of August 15, 2025. The contract involves no set-aside designation and was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Febuxostat 40 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $8,292.13 and an ultimate completion date of August 27, 2025. The contract carries no set-aside designation and represents a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $857 delivery order to Amerisourcebergen Drug Corporation for the supply of 30 tablets of 40mg Febuxostat, an oral medication used to treat hyperuricemia and gout. The delivery order was issued under an indefinite-delivery/indefinite-quantity contract vehicle and calls for shipment to a facility in Conshohocken, Pennsylvania by August 1, 2023. The award is a firm fixed-price delivery order with no set aside designations. Amerisourcebergen will fulfill the...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Febuxostat 80 mg tablets (30-count units) with a contract value of $2,965.04. The contract features firm fixed pricing and carries an ultimate completion date of August 26, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999...
- SPE2DB25D7057Indefinite Delivery Contract
- SPE2DB25D7057-SPE2DB25FXVQUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,862.32 to AmerisourceBergen Drug Corp for 30 tablets of Febuxostat 40 mg, a medication used to treat gout. The contract was competitively awarded without a set-aside designation and carries a firm fixed price structure, with an ultimate completion date of May 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this order. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's extensive federal contract portfolio demonstrates its capability to supply a diverse range of pharmaceutical products and medical commodities across multiple therapeutic domains. This specific delivery order represents a routine transaction within the company's broader relationship with DLA, contributing to the supply of medications and medical supplies necessary to support military healthcare programs and other government healthcare systems domestically and globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 5/27/25 |